Neurotrack Raises $2M From Founders Fund, Social+Capital To Predict And Diagnose The Onset Of Alzheimer’s Disease
Summary
The startup, which graduated from Rock Health’s Boston class, has developed a computer-based cognitive test that can detect the risk of Alzheimer’s Disease up to six years prior to the onset of symptoms. The science behind Neurotrack’s technology stems from 30 years of research that eventually discovered that the hippocampus is the first structure in the brain to be affected by Alzheimer’s. After hearing some of the results from early studies at Emory University a few years back, she became intrigued and teamed up with the group of scientists to figure out how they could actually bring this to market. Kaplan explains that the primary reason many drugs are failing to treat Alzheimer’s is because there hasn’t been an early diagnostic test. While Neurotrack hasn’t been distributed commercially, there are a number of clinical studies being done with the technology at Emory, Johns Hopkins and Massachusetts General Hospital.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
